Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Bevacizumab for the Treatment Hemorrhagic Hereditary Telangiectasia (HHT) Associated With Severe Hepatic Vascular Malformations. Phase II Study.

NCT00843440 is registered in ClinicalTrials.gov with Hospices Civils de Lyon as lead sponsor.

NCT NCT00843440
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00843440 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Bevacizumab for the Treatment Hemorrhagic Hereditary Telangiectasia (HHT) Associated With Severe Hepatic Vascular Malformations. Phase II Study.
Lead sponsor
Hospices Civils de Lyon
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2009
Completion date
March 31, 2012
Enrollment
25 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hemorrhagic hereditary telangiectasia